KR101010767B1 - 에포틸론을 포함하는 조성물 및 카르시노이드 증후군치료에 있어서 그의 용도 - Google Patents

에포틸론을 포함하는 조성물 및 카르시노이드 증후군치료에 있어서 그의 용도 Download PDF

Info

Publication number
KR101010767B1
KR101010767B1 KR1020047009001A KR20047009001A KR101010767B1 KR 101010767 B1 KR101010767 B1 KR 101010767B1 KR 1020047009001 A KR1020047009001 A KR 1020047009001A KR 20047009001 A KR20047009001 A KR 20047009001A KR 101010767 B1 KR101010767 B1 KR 101010767B1
Authority
KR
South Korea
Prior art keywords
formula
combination
methyl
treatment
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020047009001A
Other languages
English (en)
Korean (ko)
Other versions
KR20040066893A (ko
Inventor
존 데이비드 로터멜
에릭 하워드 루빈
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20040066893A publication Critical patent/KR20040066893A/ko
Application granted granted Critical
Publication of KR101010767B1 publication Critical patent/KR101010767B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epoxy Compounds (AREA)
KR1020047009001A 2001-12-13 2002-12-12 에포틸론을 포함하는 조성물 및 카르시노이드 증후군치료에 있어서 그의 용도 Expired - Fee Related KR101010767B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US34216701P 2001-12-13 2001-12-13
US60/342,167 2001-12-13
US41599002P 2002-10-04 2002-10-04
US60/415,990 2002-10-04
PCT/EP2002/014162 WO2003049734A1 (en) 2001-12-13 2002-12-12 Compositions comprising epothilones and their use for the treatment of carcinoid syndrome

Publications (2)

Publication Number Publication Date
KR20040066893A KR20040066893A (ko) 2004-07-27
KR101010767B1 true KR101010767B1 (ko) 2011-01-25

Family

ID=26992855

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047009001A Expired - Fee Related KR101010767B1 (ko) 2001-12-13 2002-12-12 에포틸론을 포함하는 조성물 및 카르시노이드 증후군치료에 있어서 그의 용도

Country Status (22)

Country Link
US (3) US20050020647A1 (https=)
EP (1) EP1463504B1 (https=)
JP (1) JP4672257B2 (https=)
KR (1) KR101010767B1 (https=)
CN (1) CN1602192A (https=)
AT (1) ATE330602T1 (https=)
BR (1) BR0214917A (https=)
CA (1) CA2468994A1 (https=)
CY (1) CY1105459T1 (https=)
DE (1) DE60212710T2 (https=)
DK (1) DK1463504T3 (https=)
ES (1) ES2266610T3 (https=)
HU (1) HUP0402537A3 (https=)
IL (1) IL162166A0 (https=)
MX (1) MXPA04005712A (https=)
NO (1) NO332773B1 (https=)
NZ (1) NZ533378A (https=)
PL (1) PL209147B1 (https=)
PT (1) PT1463504E (https=)
RU (1) RU2341261C2 (https=)
TW (1) TWI287986B (https=)
WO (1) WO2003049734A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001124A1 (en) 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
AU2003235761A1 (en) * 2002-01-14 2003-07-24 Novartis Ag Combinations comprising epothilones and anti-metabolites
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CA2499682A1 (en) * 2002-10-09 2004-04-22 Kosan Biosciences, Inc. Epo d + 5-fu/gemcitabine
AU2004268377B2 (en) * 2003-09-02 2008-06-26 Novartis Ag Cancer treatment with epothilones
US20050171167A1 (en) 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
AU2011255647A1 (en) 2010-05-18 2012-11-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
HUE071943T2 (hu) 2015-02-03 2025-10-28 Amryt Endo Inc Akromegália kezelése oktreotid orális alkalmazásával
RU2633266C2 (ru) * 2015-07-02 2017-10-11 Рауф Ашрафович Ашрафов Способ моделирования карциноидного синдрома
JP2025508846A (ja) * 2022-02-25 2025-04-10 アムリット・エンドゥ・インコーポレイテッド 疾患の治療のための経口オクトレオチド

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356270A (en) * 1977-11-08 1982-10-26 Genentech, Inc. Recombinant DNA cloning vehicle
US4318477A (en) * 1980-09-22 1982-03-09 Kerpe Stase Z Pharmaceutical package
US5753616A (en) * 1986-11-10 1998-05-19 Biopure Corporation Method for producing a stable polymerized hemoglobin blood-substitute
DE3845000C2 (de) * 1987-07-10 1998-11-19 Novartis Ag Anwendung von Octreotid zur Behandlung von Brustkrebs
KR20000015944A (ko) * 1996-05-24 2000-03-15 팜 윌리암 엔. 신체 통로의 질병을 치료 또는 예방하기 위한조성물 및 방법
US5969145A (en) * 1996-08-30 1999-10-19 Novartis Ag Process for the production of epothilones and intermediate products within the process
DK1367057T3 (da) * 1996-11-18 2009-01-19 Biotechnolog Forschung Gmbh Epothiloner E og F
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
DE19908760A1 (de) * 1999-02-18 2000-08-24 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
AU2001266583A1 (en) * 2000-05-26 2001-12-11 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same

Also Published As

Publication number Publication date
TWI287986B (en) 2007-10-11
PT1463504E (pt) 2006-10-31
NO332773B1 (no) 2013-01-14
IL162166A0 (en) 2005-11-20
DE60212710T2 (de) 2007-01-11
KR20040066893A (ko) 2004-07-27
HK1069983A1 (en) 2005-06-10
EP1463504A1 (en) 2004-10-06
PL369141A1 (en) 2005-04-18
TW200301113A (en) 2003-07-01
HUP0402537A3 (en) 2009-01-28
CN1602192A (zh) 2005-03-30
MXPA04005712A (es) 2004-12-06
HUP0402537A2 (hu) 2005-03-29
WO2003049734A1 (en) 2003-06-19
RU2004121687A (ru) 2005-08-10
JP4672257B2 (ja) 2011-04-20
US20050020647A1 (en) 2005-01-27
CY1105459T1 (el) 2010-04-28
ES2266610T3 (es) 2007-03-01
ATE330602T1 (de) 2006-07-15
JP2005511721A (ja) 2005-04-28
NO20042832L (no) 2004-07-05
DK1463504T3 (da) 2006-10-02
RU2341261C2 (ru) 2008-12-20
DE60212710D1 (de) 2006-08-03
US20060229345A1 (en) 2006-10-12
EP1463504B1 (en) 2006-06-21
AU2002366531A1 (en) 2003-06-23
BR0214917A (pt) 2004-11-30
CA2468994A1 (en) 2003-06-19
US20090246172A1 (en) 2009-10-01
NZ533378A (en) 2006-03-31
PL209147B1 (pl) 2011-07-29

Similar Documents

Publication Publication Date Title
US20090246172A1 (en) Compositions comprising epothilones and their use for the treatment of carcinoid syndrome
JP3784418B2 (ja) ソマトスタチン類似体およびラパマイシンの配合
US20090298791A1 (en) Combinations comprising epothilones and antimetabolites
Dunne et al. A phase 1 study to assess the pharmacokinetics of sulopenem etzadroxil (PF-03709270)
US20110251134A1 (en) Combination of (a) a dna toposomerase inhibitor and (b) an iap inhibitor
EP1251850B1 (en) Use of a combination preparation in cancer therapy
US6340696B1 (en) Viral treatment
US20110152329A1 (en) Use of Epothilone Derivatives for the Treatment of Hyperparathyroidism
EA022711B1 (ru) Комбинация дибромида 1,12-додекаметилен-бис-[4-метил-5-(2-гидроксиэтил)тиазолия] и артесуната для лечения тяжелой формы малярии
AU2002366531B2 (en) Compositions comprising epothilones and their use for the treatment of carcinoid syndrome
US20030109565A1 (en) Antipyretic preparation containing xylitol
HK1069983B (en) Compositions comprising epothilones and their use for the treatment of the carcinoid syndrome
AU2007200588A1 (en) Compositions comprising epothilones and their use for the treatment of carcinoid syndrome
US20060094766A1 (en) Epothilone derivatives for the treatment of multiple myeloma
ZA200404013B (en) Compositions comprising epothilones and their use for the treatment of carcinoid syndrome.
AU2007200677B2 (en) Combinations comprising epothilones and anti-metabolites
KR20040101274A (ko) 에포틸론 유도체 및 알킬화제를 포함하는 병용 제제
WO2004073719A1 (en) A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20140119

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20140119

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000